Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | COO, CLO, Compliance Officer | October 05, 2026 | October 06, 2026 |
| VivoSim Labs, INC.ONVO · Entity 8386 | General Counsel & Secretary | August 18, 2020 | August 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 366,159 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 8,370 · Balance 366,159 F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
VivoSim Labs, INC.
Report date August 18, 2020 · Filed August 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 192,758 |
Reported balance
After 2020-08-18 transaction · row 1
1 source rowRow 1 · 2020-08-18 · Tax withholding · Disposed 10,900 · Balance 192,758 F1: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 8,370 | $6.84 | $57,227.36 |
DisclosureSEC source: 0001193125-26-415529 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,159 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001193125-26-389511 · ownership.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2036-09-08 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 22:36 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389511 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,529 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:03 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 8,391 | $11.16 | $93,605.80 |
DisclosureSEC source: 0001193125-26-383621 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,529 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0350 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2026 Filed May 20, 2026 01:51 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 8,790 | $9.01 | $79,178.56 |
DisclosureSEC source: 0001193125-26-231508 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,920 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7439 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:49 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 3,515 | $4.00 | $14,060.00 |
DisclosureSEC source: 0001193125-26-057669 · ownership.xml · nonDerivative · entry 2 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,710 F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:49 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 117,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057669 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,225 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 20,519 | Not disclosed Strike: $13.47 | Not disclosed |
DisclosureSEC source: 0001193125-25-317981 · ownership.xml · derivative · entry 5 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,519 shares Expires 2034-05-01 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F6 · derivative.exercise_date: 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 14,202 | Not disclosed Strike: $5.18 | Not disclosed |
DisclosureSEC source: 0001193125-25-317981 · ownership.xml · derivative · entry 4 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,202 shares Expires 2034-01-23 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F5 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,119 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317981 · ownership.xml · derivative · entry 3 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,119 shares Expires 2033-05-23 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F4 · derivative.exercise_date: Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 41,039 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317981 · ownership.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,039 shares Expires 2033-04-02 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F3 · derivative.exercise_date: 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 84,877 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-317981 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,925 F1 · shares: Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 01:38 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 3,055 | $3.25 | $9,928.75 |
DisclosureSEC source: 0001193125-25-285006 · ownership.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,048 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 6,409 | $2.75 | $17,624.75 |
DisclosureSEC source: 0001415889-25-022221 · form4-08182025_080803.xml · nonDerivative · entry 2 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,103 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| May 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 1,937 | $2.13 | $4,125.81 |
DisclosureSEC source: 0001415889-25-022221 · form4-08182025_080803.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,512 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 86,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006033 · form4-02282025_050201.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,449 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 20:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023360 · form4-09132024_040904.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · COO, CLO, Secy, Compliance Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,799 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 22:21 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 10,900 | $0.57 | $6,204.28 |
DisclosureSEC source: 0001209191-20-047289 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,758 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:22 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 14,630 | $0.51 | $7,508.12 |
DisclosureSEC source: 0001209191-20-031010 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,658 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 00:25 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 13,850 | $0.32 | $4,423.69 |
DisclosureSEC source: 0001209191-20-011300 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,288 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:20 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 11,695 | $0.45 | $5,254.56 |
DisclosureSEC source: 0001209191-19-057256 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,138 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 22:18 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 11,960 | $0.29 | $3,415.78 |
DisclosureSEC source: 0001209191-19-046689 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,833 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:42 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 12,275 | $0.97 | $11,906.75 |
DisclosureSEC source: 0001209191-19-031488 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,793 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,589,126 shares of common stock. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:52 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 13,520 | $1.07 | $14,408.26 |
DisclosureSEC source: 0001209191-19-012219 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,068 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,601,401 shares of common stock. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 22:40 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 11,915 | $1.07 | $12,716.88 |
DisclosureSEC source: 0001209191-18-059489 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,588 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,614,921 shares of common stock. Read SEC document |
| August 16, 2018 Filed Aug 16, 2018 22:58 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 12,400 | $1.11 | $13,733.00 |
DisclosureSEC source: 0001209191-18-047195 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,503 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, June 2017 and May 2018, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 1,333,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 1,626,836 shares of common stock. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 22:58 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 675,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-18-047195 · doc4.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2028-08-15 F3 · derivative.exercise_date: 25% of the option shares vest and become exercisable on August 15, 2019 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:36 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 283,333 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-18-033917 · doc4.xml · derivative · entry 2 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,333 Underlying: Common Stock · 283,333 shares Expires 2028-05-24 F4 · derivative.exercise_date: The option shares vest and become exercisable over 16 equal quarterly installments measured from May 15, 2018. Read SEC document |
| May 24, 2018 Filed May 29, 2018 21:36 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 70,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033917 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,903 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2018. F3 · balance_after: This number does not include 658,333 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 964,236 shares of common stock. Read SEC document |
| May 16, 2018 Filed May 17, 2018 21:39 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 9,160 | $1.66 | $15,224.84 |
DisclosureSEC source: 0001209191-18-031104 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,655 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 610,655 shares of common stock. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 13:50 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 10,365 | $1.09 | $11,251.21 |
DisclosureSEC source: 0001209191-18-011100 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,815 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 619,815 shares of common stock. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 00:45 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 8,900 | $1.47 | $13,084.78 |
DisclosureSEC source: 0001209191-17-061322 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,180 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 630,180 shares of common stock. Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 20:48 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 5,871 | $2.06 | $12,094.26 |
DisclosureSEC source: 0001209191-17-049421 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,080 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016 and June 2017, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 639,080 shares of common stock. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:11 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 190,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042349 · doc4.xml · nonDerivative · entry 2 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,951 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F3 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. The RSUs vest and settle over 16 equal quarterly installments measured from May 15, 2017. F4 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush beneficially owns or has a right to acquire 644,951 shares of common stock. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:11 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-042349 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,951 F1 · security: Annual long-term equity award approved by the Compensation Committee of the Issuer's Board of Directors. F2 · shares: The shares represent a grant of Restricted Stock Units ("RSUs"). The RSUs represent a right to receive shares of the Issuer's common stock, at no additional conversion or exercise price. 25% of the RSUs vest and settle on November 15, 2017 and the remaining RSUs vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| May 16, 2017 Filed May 17, 2017 23:06 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,235 | $2.86 | $3,534.69 |
DisclosureSEC source: 0001209191-17-033414 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,951 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush continues to beneficially own or have a right to acquire 419,951 shares of common stock. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 22:57 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,390 | $2.95 | $4,100.50 |
DisclosureSEC source: 0001209191-17-012843 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,186 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush continues to beneficially own or have a right to acquire 421,186 shares of common stock. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 22:04 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | Tax withholdingCommon Stock | 1,210 | $3.26 | $3,943.87 |
DisclosureSEC source: 0001209191-16-151265 · doc4.xml · nonDerivative · entry 1 Bush Jennifer · CIK 0001621152 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,576 F1 · shares: Represents the mandatory sale of shares to satisfy the Reporting Person's tax withholding obligations, in connection with the partial vesting and settlement of restricted stock units granted in July 2016, pursuant to the Reporting Person's agreement with the Issuer. F2 · balance_after: This number does not include 375,000 shares of common stock underlying outstanding options held by Ms. Bush; post-transaction Ms. Bush continues to beneficially own or have a right to acquire 422,576 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.